Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2009, Article ID 378287, 3 pages
http://dx.doi.org/10.1155/2009/378287
Case Report

Myopathy with Concurrent Tadalafil and Simvastatin

Department of Senescence, Urological and Neurological Sciences Ospedale Cannizzaro, Viale Messina, 95125 Catania, Italy

Received 21 April 2009; Accepted 1 July 2009

Academic Editor: Helmy M. Siragy

Copyright © 2009 Maria Pia Gargante et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Kendirci, S. Nowfar, and W. J. Hellstrom, “The impact of vascular risk factors on erectile function,” Drugs of Today, vol. 41, no. 1, pp. 65–74, 2005. View at Publisher · View at Google Scholar · View at PubMed
  2. B. J. Ring, B. E. Patterson, M. I. Mitchell et al., “Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo,” Clinical Pharmacology and Therapeutics, vol. 77, no. 1, pp. 63–75, 2005. View at Publisher · View at Google Scholar · View at PubMed
  3. T. Prueksaritanont, B. Ma, and N. Yu, “The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6,” British Journal of Clinical Pharmacology, vol. 56, no. 1, pp. 120–124, 2003. View at Publisher · View at Google Scholar
  4. G. M. Rosano, A. Aversa, C. Vitale, A. Fabbri, M. Fini, and G. Spera, “Chronic treatment with Tadalafil improves endothelial function in men with increased cardiovascular risk,” European Urology, vol. 47, no. 2, pp. 214–222, 2005. View at Publisher · View at Google Scholar · View at PubMed
  5. H. Solomon, A. S. Wierzbicki, P. J. Lumb, M. Lambert-Hammill, and G. Jackson, “Cardiovascular risk factors determine erectile and arterial function response to Sildenafil,” American Journal of Hypertension, vol. 19, no. 9, pp. 915–919, 2006. View at Publisher · View at Google Scholar · View at PubMed
  6. A. L. Burnett, C. J. Lowenstein, D. S. Bredt, T. S. Chang, and S. H. Snyder, “Nitric oxide: a physiologic mediator of penile erection,” Science, vol. 257, no. 5068, pp. 401–403, 1992. View at Google Scholar
  7. J. Rajfer, W. J. Aronson, P. A. Bush, F. J. Dorey, and L. J. Ignarro, “Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission,” The New England Journal of Medicine, vol. 326, no. 2, pp. 90–94, 1992. View at Google Scholar
  8. R. C. Kukreja, F. Salloum, A. Das et al., “Pharmacological preconditioning with sildenafil: basic mechanisms and clinical implications,” Vascular Pharmacology, vol. 42, no. 5-6, pp. 219–232, 2005. View at Publisher · View at Google Scholar · View at PubMed
  9. K. Rizvi, J. P. Hampson, J. N. Harvey et al., “Do lipid-lowering drugs cause erectile dysfunction? A systematic review,” Family Practice, vol. 19, no. 1, pp. 95–98, 2002. View at Google Scholar
  10. C. A. Gutierrez, “Sildenafil-simvastatin interaction: possible cause of rhabdomyolysis?” American Family Physician, vol. 63, no. 4, pp. 636–637, 2001. View at Google Scholar
  11. T. R. Pedersen and O. Faergeman, “Simvastatin seems unlikely to cause impotence,” British Medical Journal, vol. 318, no. 7177, p. 192, 1999. View at Google Scholar
  12. P. J. Neuvonen, M. Niemi, and J. T. Backman, “Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance,” Clinical Pharmacology and Therapeutics, vol. 80, no. 6, pp. 565–581, 2006. View at Publisher · View at Google Scholar · View at PubMed